Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.

Published

Journal Article

BACKGROUND: The purpose of the current study was to evaluate the efficacy and tolerance of the noncisplatin-based combination of paclitaxel and gemcitabine administered weekly for patients with untreated metastatic nonsmall cell lung cancer (NSCLC). METHODS: Patients with Stage IIIB/IV or recurrent NSCLC, a performance status of 0-2, and no prior chemotherapy exposure were eligible. Patients received gemcitabine 1000 mg/m2 and paclitaxel 85 mg/m2 on Days 1, 8, 15, 22, 29, 36 of an 8-week cycle until progression. RESULTS: Thirty-nine eligible patients were enrolled. The median age was 66 years and 14 patients were > or =70 years old. Performance status was 2 in 13 (33%) and 29 patients (75%) had Stage IV. Five patients (12.8%) developed interstitial pneumonitis and 2 of these were responsive to steroid therapy. The overall response rate was 23.1%, with no complete responses. The median survival was 32 weeks and the 1-year survival was 32%. CONCLUSIONS: This regimen of weekly paclitaxel and gemcitabine has modest activity in advanced NSCLC.

Full Text

Duke Authors

Cited Authors

  • Akerley, W; Safran, H; Zaner, K; Ready, N; Mega, T; Kennedy, T

Published Date

  • September 1, 2006

Published In

Volume / Issue

  • 107 / 5

Start / End Page

  • 1050 - 1054

PubMed ID

  • 16878327

Pubmed Central ID

  • 16878327

International Standard Serial Number (ISSN)

  • 0008-543X

Digital Object Identifier (DOI)

  • 10.1002/cncr.22095

Language

  • eng

Conference Location

  • United States